CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has received an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.8333.

Several equities research analysts recently issued reports on CYRX shares. Needham & Company LLC raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. UBS Group increased their price target on shares of CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. BTIG Research lifted their price target on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $9.40 on Friday. The company has a market cap of $470.66 million, a P/E ratio of 8.03 and a beta of 1.51. The business has a fifty day simple moving average of $9.43 and a 200-day simple moving average of $8.48. CryoPort has a 52 week low of $4.58 and a 52 week high of $11.44. The company has a quick ratio of 15.01, a current ratio of 15.77 and a debt-to-equity ratio of 0.40.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $44.23 million for the quarter, compared to analyst estimates of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. Equities research analysts forecast that CryoPort will post -0.99 EPS for the current year.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total value of $115,584.30. Following the transaction, the director directly owned 80,758 shares in the company, valued at $806,772.42. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in CryoPort by 154.5% during the 1st quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company’s stock worth $199,000 after acquiring an additional 19,886 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of CryoPort during the second quarter valued at approximately $292,000. Assenagon Asset Management S.A. lifted its position in shares of CryoPort by 7.3% during the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company’s stock worth $8,135,000 after purchasing an additional 73,949 shares in the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of CryoPort by 55.9% during the second quarter. Conestoga Capital Advisors LLC now owns 110,557 shares of the company’s stock worth $825,000 after purchasing an additional 39,640 shares in the last quarter. Finally, Thematics Asset Management boosted its stake in shares of CryoPort by 12.8% in the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after purchasing an additional 216,937 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.